Successful use of recombinant factor VIIa for emergency fasciotomy in a patient with hemophilia A and high‐titer inhibitor unresponsive to factor VIII inhibitor bypassing activity

We report a patient with hemophilia A and high‐titer factor VIII inhibitor who developed compartment syndrome of his forearm following trauma. Emergency fasciotomy was performed. Initial hemostatic treatment with factor VIII inhibitor bypassing activity (FEIBA) was unsuccessful. Bleeding was controlled with recombinant factor VIIa. Am. J. Hematol. 79:58–60, 2005. © 2005 Wiley‐Liss, Inc.

[1]  Y. Nakatomi,et al.  A novel therapeutic approach combining human plasma‐derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone , 2003, Vox sanguinis.

[2]  C. Bruggers,et al.  Successful treatment of acquired factor VIII deficiency in a child using activated factor VII concentrates: case report and review of the literature. , 2003, Journal of pediatric hematology/oncology.

[3]  J. Astermark,et al.  Factor VIII Inhibitor-Bypassing Agents Act by Inducing Thrombin Generation and Can Be Monitored by a Thrombin Generation Assay , 2003, Pathophysiology of Haemostasis and Thrombosis.

[4]  G. Nelsestuen,et al.  Possible Synergy between Recombinant Factor VIIa and Prothrombin Complex Concentrate in Hemophilia Therapy , 2002, Thrombosis and Haemostasis.

[5]  Z. Rahimtoola,et al.  TWO CASES OF ACUTE CARPAL TUNNEL SYNDROME IN CLASSIC HAEMOPHILIA , 2002, Scandinavian journal of plastic and reconstructive surgery and hand surgery.

[6]  L. Aledort,et al.  On the treatment of hemorrhage in patients with hemophilia and associated inhibitors , 2001, Transfusion.

[7]  M. Poon,et al.  Therapeutic choices for patients with hemophilia and high‐titer inhibitors , 2001, American journal of hematology.

[8]  J. Ingerslev,et al.  Management and monitoring of recombinant activated factor VII , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[9]  D. Monroe,et al.  The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell‐based model of coagulation , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[10]  J. Ingerslev,et al.  Efficacy and Safety of Recombinant Factor VIIa in the Prophylaxis of Bleeding in Various Surgical Procedures in Hemophilic Patients with Factor VIII and Factor IX Inhibitors , 2000, Seminars in thrombosis and hemostasis.

[11]  W. Kreuz,et al.  German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  Scharrer,et al.  Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentrates , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  J. Gill,et al.  Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors , 1998, Thrombosis and Haemostasis.

[14]  C. Kessler,et al.  Immune tolerance: a synopsis of the international experience , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  C. Kessler,et al.  Unsolved problems in haemophilia , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  L. Aledort,et al.  Inhibitors occur more frequently in African–American and Latino Haemophiliacs , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  J. Lusher,et al.  Clinical experience with recombinant factor VIIa. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[18]  J. Esterhai,et al.  Treatment of considerations in patients with compartment syndrome and an inherited bleeding disorder. , 1997, Orthopedics.

[19]  C. Rothschild,et al.  Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX Inhibitors , 1997, Thrombosis and Haemostasis.

[20]  W. Kreuz,et al.  Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs , 1992, The Lancet.

[21]  S. Gordon,et al.  A fast new medium in haemostasis and thrombosis , 1990 .

[22]  G. Knatterud,et al.  The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. , 1983, Blood.

[23]  A. Girolami,et al.  Factor X survival and therapeutic factor X levels in the abnormal factor X (factor X FRIULI) COAGULATION DISORDER. , 1974, Acta haematologica.